Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 39Recruiting 5Terminated 3Withdrawn 2Active not recruiting 2Unknown 1Enrolling by invitation 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 2Other 1Lymphoid 1Genitourinary 1

Conditions

Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Obesity 1Neoplasms 1Lymphoma, Non-Hodgkin 1Inflammation 1Hodgkin Disease 1Chemotherapy Effect 1

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Interventional × Omeprazole × Clear all
NCT07214662 2026-06-03

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

Genentech, Inc.

Phase 1 Recruiting
136 enrolled
Breast

Breast Neoplasms

NCT04337580 2026-04-13

FASN

Wake Forest University Health Sciences

Phase 2 Recruiting
50 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06510010 2026-01-26

Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Recruiting
198 enrolled

Chemotherapy Effect

NCT06383338 2025-09-08

PEGASUS

Murdoch Childrens Research Institute

Phase 1 Recruiting
10 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT06150898 2025-06-13

KePreSt

Jules Bordet Institute

Phase 2 Recruiting
112 enrolled
BreastOther

Breast Neoplasms, Inflammation, Obesity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡